Psychiatry

In an interview, King provided an overview of the history of psychedelic research for psychiatric conditions, where we are now, and what hurdles investigators must address.

At APA 2024, Weinrieb discussed the positive patient outcomes of using a psychiatry-hepatology approach for the treatment of alcohol-associated liver disease.

Sibille and colleagues have made progress in refining the therapeutic pathways of Alzheimer disease. Human trials may soon follow.

Phillips emphasizes the importance of screening for obsessive-compulsive disorders, such as OCD, body dysmorphic disorder, and trichillomania.

In an interview with HCPLive, Jha said clinicians should think of interventional approaches for treatment-resistant depression “sooner rather than later.”

McIntyre discusses how GLP-1 and GIP receptor agonists like semaglutide could potentially improve both acute and long-term measures of psychiatric disease.

In an interview, Phillip explained the difference between OCD and body dysmorphic disorder, even though they are grouped in the DSM-5.

In an interview with HCPLive, Barnett discussed the ethical concerns of using psychedelics for treating substance use disorders.

In an interview with Adler at APA 2024, he also explained how adults with ADHD may present additional symptoms not noted on the DSM when they have comorbidities.

Compass Pathways reports positive results for psilocybin in PTSD treatment, showing safety and symptom improvement in an open-label phase 2 study.

Robert O. Cotes, MD, discusses why the proven agent clozapine may still be underutilized in schizophrenia.

In an interview with HCPLive, Karlin and Robinson discuss the phase 2b trial on MM120 for generalized anxiety disorder.

In an interview with HCPLive, Karlin discussed the unmet need for GAD screening.

At APA 2024, HCPLive interviewed APA members about how DSM-5-TR classifies psychiatric disorders differently than previous iterations.

Nelson discusses how personality disorder care has been slow to apply evidence into practice—and how it's affecting patients.

In an interview, Paul Appelbaum, MD, discussed issues clinicians will need to bring up to their patients if the FDA approves a psychedelic-assisted therapy.

Lykos Therapeutics' new drug application for MDMA plus psychiatric intervention for adults with PTSD will be the first reviewed by an FDA committee for such a therapy.

The utility of second-generation antipsychotics and clozapine has been less advantageous than it could be, Kane explained.

In an interview, Ryan McLaughlin discussed the ethical concerns regarding treating psychiatric illness with cannabis.

McIntyre explains why GLP-1/GIP receptor agonists like semaglutide may alter cognitive and psychiatric care similar to cardiometabolic disease.

Devanand reviews lecanemab and the advent of blood biomarkers for dementia and Alzheimer's management at APA 2024.

Marmar explains what anticipated blood and molecular profiling of PTSD may provide psychiatrists treating patients.

Kane explains why newer long-acting injectables and clozapine may be under-utilized still in the management of schizophrenia.

In an interview with Andrew Chen, MD, he explained why patients might need to turn to more adverse event prone anxiety medications.

Despite often presenting to the hospital with similar non-psychiatric conditions, patients with schizophrenia often experience a more difficult care process than those without.